BPG is committed to discovery and dissemination of knowledge
Review
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Hepatol. Nov 27, 2026; 18(11): 125343
Published online Nov 27, 2026. doi: 10.4254/wjh.125343
Hepatitis B surface antigen-targeting strategies for clearance: A review of progress from mechanistic exploration to clinical translation
Li Wang
Li Wang, Department of Hepatology, Yantai Qishan Hospital, Yantai 264001, Shandong Province, China
Li Wang, Department of Clinical Laboratory, Yantai Qishan Hospital, Yantai 264001, Shandong Province, China
Author contributions: Wang Li conceived the topic, wrote the article, drew the figures, and revised the article.
AI contribution statement: The image was drawn on the website https://jova.ai/ai-image-generator (AI tool: Jova.ai). The authors take full responsibility and accountability for all content of this manuscript, including any portions for which AI tools were used as assistive technologies. All AI-assisted outputs were carefully reviewed, validated, and approved by the authors. AI tools were not used to generate original scientific data, perform independent scientific analyses, or draw scientific conclusions.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Corresponding author: Li Wang, PhD, Associate Professor, Department of Hepatology, Yantai Qishan Hospital, No. 62 Huanshan Road, Zhifu District, Yantai 264001, Shandong Province, China. liliwang2200@163.com
Received: July 9, 2026
Revised: August 2, 2026
Accepted: October 20, 2026
Published online: November 27, 2026
Processing time: 137 Days and 22.9 Hours
Abstract

Hepatitis B surface antigen (HBsAg) persistence hinders the achievement of a functional cure in patients with chronic hepatitis B. Strategies to suppress or eliminate HBsAg and break the host immune tolerance while restoring immune response become key components of immune therapy-directed clinical cure. Agents that target HBsAg include monoclonal antibodies, small interfering RNAs, antisense oligonucleotides, gene editing technologies, capsid assembly modulators, and therapeutic agents targeting secretion pathways. Immune checkpoint inhibitors and other immune-based clearance approaches are also included within this strategic framework. These agents target the HBsAg lifecycle and its source templates, including covalently closed circular DNA and integrated hepatitis B virus DNA in the host genome. This article reviews these strategies by synthesizing the latest information from preclinical studies and clinical trials, summarises their mechanisms and efficacy, discusses challenges and prospects for combinations, and aims to provide a scientific basis for chronic hepatitis B curative research.

Keywords: Hepatitis B surface antigen clearance; Functional cure; Monoclonal antibodies; RNA interference; Gene editing; Immunoregulatory agents; Combination strategy

Core Tip: Hepatitis B surface antigen persistence is the primary driver of immune tolerance in chronic hepatitis B. Strategies that reduce or eliminate hepatitis B surface antigen to break host immune tolerance and reinvigorate an immune response are emerging as promising therapeutic avenues for clinical cure. These therapeutic modalities include monoclonal antibodies, small interfering RNAs, antisense oligonucleotides, gene-editing technologies, capsid assembly modulators, agents targeting secretory pathways, and immune-based clearance strategies. Combination strategies have shown synergistic effects. Future clinical trial designs must prioritize identifying optimal combinations that maximize synergy while minimizing toxicity.

Write to the Help Desk